In Australia, provided domestic supply of medicinal cannabis is not affected, the following products are eligible for export if granted a licence and permit to export.
Medicinal cannabis products manufactured in Australia under a GMP licence.
Medicinal cannabis products listed as export-only, or registered, on the Australian Register of Therapeutic Goods (ARTG).
Extracts of cannabis (or extracts of cannabis resin) manufactured under a Narcotic Drugs Act 1967 licence and permit that are not in the final dosage form.
Note: Cannabis or cannabis resin that has not undergone processing under a GMP licence may not be exported.
The 5 year target for BBS is to be “The leading” medicinal Cannabis cultivator and manufacturer in Australia, to have strong market connections at a global level, as well as influence the Australian and South east Asian market as leader in this industry.
The BBS board with the guidance and leadership of their CEO, have developed a sound business growth strategy under an operational framework. Currently the team is working on the final phase of the planning and development of the facility with Local, State and Federal Government oversee. Under the guidance of their newly appointed CEO and their strategic advisors, the board has developed a business ready, operational framework and a robust business plan which includes capital costs, operation expenditure as well as operational revenue forecasting.